Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 GlobeNewswire - Mon Dec 29, 2025

Mission-aligned community focused on accelerating breakthroughs in Alzheimer’s disease, Parkinson’s disease and related conditions Supported by Health Moonshot Champions, including the Alzheimer’s...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy GlobeNewswire - Wed Dec 17, 2025

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle BayStreet.ca - Tue Dec 16, 2025

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 0.5576 (+1.71%)
AVAI : 0.6888 (+13.57%)
BIOA : 22.92 (+10.78%)
GAA : 33.27 (+0.59%)
DNLI : 18.27 (+0.88%)
MAPT : 0.0003 (unch)
KLTO : 0.3019 (-6.04%)
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum GlobeNewswire - Wed Dec 3, 2025

MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging GlobeNewswire - Tue Dec 2, 2025

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) GlobeNewswire - Mon Dec 1, 2025

Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025) GlobeNewswire - Wed Nov 19, 2025

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy GlobeNewswire - Wed Nov 12, 2025

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging No approved...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire - Tue Nov 4, 2025

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 GlobeNewswire - Tue Oct 28, 2025

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.5576 (+1.71%)
LGVNR : 0.0005 (-37.50%)

Barchart Exclusives

2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income Barchart - Wed Jan 14, 6:30PM CST
These two income stocks can weather every cycle. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot